Reboxetine, sold under the brand name Edronax among others, is a selective norepinephrine reuptake inhibitor (sNRI) medication marketed as an antidepressant by Pfizer for use in the treatment of major depressive disorder, although it has also been used off label for other indications in research settings. Chemically it is a racemic oxazolidinone derivative that inhibits the norepinephrine transporter with much greater selectivity than for the serotonin transporter, producing increased synaptic norepinephrine. Pharmacokinetic characteristics include good oral absorption, hepatic metabolism with contribution from cytochrome P450 pathways, and renal excretion of metabolites. Clinically relevant properties include a time to peak concentration on the order of a few hours and an elimination half life that supports twice daily dosing in many regimens. The safety profile is dominated by noradrenergic effects such as dry mouth, constipation, insomnia, increased heart rate and blood pressure in some patients; interactions with strong CYP inhibitors or inducers and with other noradrenergic drugs warrant monitoring. Analytical characterization for quality control typically uses HPLC and LC-MS methods to confirm identity, assay, dissolution and impurity profile.
Parent: Reboxetine
Typical related compounds and impurities encountered during synthesis, storage and metabolism include N-desethyl reboxetine (N-dealkylation product), mono and dihydroxylated positional isomers, N-oxide derivatives and trace process- or solvent-related contaminants; oxidative and hydrolytic degradants can also be observed under forced-degradation conditions. In pharmaceutical quality specifications known/qualified related substances are ordinarily limited to low single-digit fractions of a percent, with common acceptance ranges being individual qualified impurities at or below about 0.1 to 0.2 percent and total impurities controlled to approximately 0.5 to 1.0 percent depending on regulatory context and maximum daily dose. Genotoxic or otherwise unqualified impurities are controlled to much lower levels in line with ICH guidance, and residual solvents are limited according to ICH Q3C class limits. Routine batch release and stability testing rely on validated HPLC-UV/PDA and LC-MS/MS methods to quantify and identify related substances and degradation products.
Reboxetine selectively blocks the norepinephrine transporter (NET), reducing neuronal reuptake of norepinephrine and thereby increasing extracellular norepinephrine concentrations; its activity at the serotonin transporter is minimal, giving it a predominantly noradrenergic profile.
Reboxetine is approved in some countries for the treatment of major depressive disorder; it has also been evaluated and occasionally used off label in research or clinical practice for other conditions where noradrenergic modulation may be beneficial.
Yes, reboxetine is classified as a selective norepinephrine reuptake inhibitor, sometimes abbreviated sNRI to emphasize its primary selectivity for the norepinephrine transporter rather than broad dual serotonin-norepinephrine inhibition.
Reboxetine is not a standard or widely approved treatment for attention deficit hyperactivity disorder; while its noradrenergic mechanism is of theoretical interest for ADHD and off-label use has been described in some reports, it is not commonly recommended as first-line ADHD therapy and evidence is limited.
